Cytonus expands its Scientific Advisory Board with City of Hope’s Stephen Forman, MD and NYU’s Robert Schneider, PhD

Share Article

Industry Key Opinion Leaders (KOLs) join Cytonus' Scientific Advisory Board (SAB)

Cytonus today announced that the company has expanded its Scientific Board of Advisors with the appointments of Stephen J. Forman, MD, Director of the Hematologic Malignancies Research Institute and the T Cell Therapeutics Research Laboratory at City of Hope, and Robert J. Schneider, PhD, New York University’s Albert Sabin Professor of Molecular Pathogenesis and the inaugural Associate Dean for NYU Technology Ventures and Partnerships.

“It is a great privilege for Cytonus to be joined by Stephen Forman and Robert Schneider, each of whom has contributed important advances in the field of medicine,” commented Cytonus’ Founder and Chief Scientific Officer, Richard Klemke, PhD.

“The expertise and multi-disciplinary perspectives of Dr. Forman and Dr. Schneider will help accelerate the realization of our shared vision for Cytonus,” commented Cytonus’ Founder and CEO Remo Moomiaie-Qajar, MD.

Cytonus’ Scientific Advisory Board (SAB) is comprised of accomplished business leaders, distinguished research scientists, and key opinion leaders (KOLs) from prestigious academic institutions, immune-oncology centers, cell therapy centers, and private industry.

  • Stephen J. Forman, MD, FACP is a internationally recognized clinician/scientist whose current focus is cancer immunotherapy — using the body's own immune system to attack cancer. Dr. Forman is the co-editor of Thomas’ Hematopoietic Cell Transplantation, a definitive textbook for clinicians, scientists and healthcare professionals. Dr. Forman exudes the special blend of zealous determination and compassion typical of City of Hope. During his 4 decades at City of Hope, Dr. Forman has been instrumental in helping to advance survival rates for cancers of the blood and immune system. Much of his current work centers on CAR T cells and their cancer-fighting potential for treatment of hematologic malignancy and solid tumors.
  • Robert Schneider, PhD is New York University’s Albert Sabin Professor of Molecular Pathogenesis, and for seven years until 2020 the Associate Dean for NYU Technology Ventures and Partnerships (the technology, commercialization and therapeutics discovery office of NYU), Professor of Radiation Oncology, and Co-Director of the Breast Cancer Research Program at NYU School of Medicine. Professor Schneider’s research focuses on three major areas: (i) translational regulation of advanced breast cancers and the development of new treatment strategies and therapeutics for advanced cancers; (ii) translational regulation of the immune response and applications in development of immune-oncology therapeutics; and (iii) regulation of adult tissue stem cells and tissue regeneration controlled by targeted mRNA decay and translational regulation.

About Cytonus Therapeutics, Inc.

Cytonus Therapeutics Inc. is a San Diego-based biotech company that has developed a vast platform of proprietary immunotherapeutic products to treat a wide range of medical conditions including cancers, infectious diseases, inflammatory diseases and cognitive disorders, and to improve patient outcomes. Its proprietary Cargocyte™ technologies are next-generation biomolecular delivery devices which have numerous medical applications across unmet therapeutic areas. Cargocytes™ are engineered to safely transport a multiplicity of therapeutic payloads into difficult-to-reach targeted tissues, and can be programmed to deliver selective, potent, and controllable "off-the-shelf" therapies. Cytonus' vast platform of therapeutics and vaccines has the potential to improve the health and lives of people with life-threatening conditions. For more information, we invite you to visit the Cytonus website at Please follow us on Cytonus on LinkedIn and on Twitter at: @CytonusTx.

Statements in this news release other than strictly historical facts, such as statements about Cytonus' plans and strategies, new and existing products and technologies, anticipated clinical and regulatory pathways, and markets for its products, are forward-looking statements. The words "believe," "expect," "aim," "anticipate," "estimate," "project," and similar expressions identify forward-looking statements that speak only as of the date hereof. Such statements involve risks and uncertainties that could cause actual results to differ materially from anticipated results due to many factors, including regulatory and development risks. The company undertakes no obligation to publicly update or revise any forward-looking statement. This news release is neither an offer to sell, nor the solicitation of any offer to purchase, any security.

Join Cytonus on LinkedIn and follow its Twitter account at: @CytonusTx

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Henry Gillespie
Visit website